CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today highlighted its recent clinical and business progress and reported its financial results for the second quarter ...
- Data from Clinical Trials of IPI-145 to be Presented at ACR and ASH - - Patient Enrollment Completed for Phase 2 Trial of Retaspimycin HCl Plus Docetaxel in Non-Small Cell Lung Cancer - -Updated ...
For some, it's the last real taste of innocence, and the first real taste of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback